CARsgen Reports Stable Share Base in October as 0.25 Million Options Lapse

Bulletin Express11-05

CARsgen Therapeutics Holdings Limited (CARsgen) filed its Monthly Return for the period ended 31 October 2026, showing no change in either authorised or issued share capital during the month.

Authorised and Issued Capital • Authorised share capital remained at 200.00 billion ordinary shares with a par value of USD 0.00000025, equivalent to USD 50,000. • Issued shares stood unchanged at 594.25 million, and the company continued to hold no treasury shares. • Public float met the Main Board’s minimum 25% requirement.

Equity Incentive Schemes • Post-IPO Share Option Scheme: Outstanding options declined by 247,375 to 16.94 million after lapses; no new grants or exercises occurred. The scheme still allows up to 16.94 million shares to be issued, with an additional 24.22 million shares available for future grants. • 2019 Equity Incentive Plan: 2.16 million shares remain available for issuance. • Post-IPO RSU Scheme: no shares remain available.

Share Repurchases • A previously disclosed 711,000 shares repurchased in July 2026 remain pending cancellation; no repurchase or cancellation activity occurred in October.

Capital Movements and Cash Flows • No new shares were issued and no treasury shares were transferred during the month. • No proceeds were raised from option exercises in October.

Overall, CARsgen’s equity structure remained static in October 2026, with minor option lapses reducing potential dilution while maintaining full compliance with Hong Kong Stock Exchange public-float requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment